<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD01800000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P22888</UniProt_ID>
  <Seq_Length>699</Seq_Length>
  <Molecule_Weight>78643</Molecule_Weight>
  <KEGG_ID>hsa:3973</KEGG_ID>
  <Orthology_ID>K04248</Orthology_ID>
  <Function_Summary>Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.</Function_Summary>
  <Pfam_ID>PF00001:7tm_1</Pfam_ID>
  <Allosteric_Activator_Count>2</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>25</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Short name=LHR</Alias>
      <Alias>Luteinizing hormone receptor</Alias>
      <Alias>Short name=LSH-R</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Combining with the choriogonadotropin hormone to initiate a change in cell activity.</Detail>
      <Keyword>Choriogonadotropin hormone receptor activity</Keyword>
      <Ontology_ID>GO:0035472</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with luteinizing hormone (also called lutropin) to initiate a change in cell activity.</Detail>
      <Keyword>Luteinizing hormone receptor activity</Keyword>
      <Ontology_ID>GO:0004964</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>368</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>144</Position>
      <Original>Val</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>625</Position>
      <Original>Ile</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>616</Position>
      <Original>Ser</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>343</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>131</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>291</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>306</Position>
      <Original>Ser</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>578</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>572</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>564</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>575</Position>
      <Original>Ile</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>578</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>577</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>578</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>578</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>284</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>502</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>593</Position>
      <Original>Ala</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>571</Position>
      <Original>Met</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>564</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>543</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>354</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>373</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>542</Position>
      <Original>Ile</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>152</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>568</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>312</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>457</Position>
      <Original>Leu</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>581</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>398</Position>
      <Original>Met</Original>
      <Variation>Thr</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of inositol trisphosphate.</Detail>
      <Keyword>Positive regulation of inositol trisphosphate biosynthetic process</Keyword>
      <Ontology_ID>GO:0032962</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand, followed by the activation of phospholipase C and the subsequent release of inositol trisphosphate.</Detail>
      <Keyword>Activation of phospholipase C activity by G-protein coupled receptor protein signaling pathway coupled to IP3 second messenger</Keyword>
      <Ontology_ID>GO:0007200</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal, e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light, and ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell, and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.</Detail>
      <Keyword>Signal transduction</Keyword>
      <Ontology_ID>GO:0007165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the male genitalia over time, from its formation to the mature structure.</Detail>
      <Keyword>Male genitalia development</Keyword>
      <Ontology_ID>GO:0030539</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand.</Detail>
      <Keyword>G-protein coupled receptor protein signaling pathway</Keyword>
      <Ontology_ID>GO:0007186</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that initiates the activity of the inactive enzyme adenylate cyclase.</Detail>
      <Keyword>Activation of adenylate cyclase activity</Keyword>
      <Ontology_ID>GO:0007190</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process which activates, maintains or increases the frequency, rate or extent of cAMP-mediated signaling, a series of molecular signals in which a cell uses cyclic AMP to convert an extracellular signal into a response.</Detail>
      <Keyword>Positive regulation of cAMP-mediated signaling</Keyword>
      <Ontology_ID>GO:0043950</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gonadotropin stimulus.</Detail>
      <Keyword>Cellular response to gonadotropin stimulus</Keyword>
      <Ontology_ID>GO:0071371</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLPVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFINLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLKLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSYGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENFSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYDFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDSQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRLRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFFIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLITVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYTSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC</Protein_Seq>
    <DNA_Seq>AGAGGGGTGCGGGCCGCACTCAGAGGCCGTCCAAGACACTGGCAAGCCGCAGAAGCCCAGTTCGCCGGCCATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCGCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCTGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGTGCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTTTCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATGCTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTGCCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTCATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAACTGTTACATCAGTAACTGCATTATTGAATTGTTCTTAAACCTGTAAAAAAAAATTACCTGTACCAGTAATTTTAACATAAAGGGTTGGATTTAGGAAATTATTTATTTTTAGGTACATTAGGCAAGAGACCTCTACCTAGTAGAAAGTGTAGTCTATGACCACTGCCACACTAAAAACTATTTGTCATTGTTACATGGCATAAATACTGAAGTTGAGAGTGTTTAGAAATTTTTATAGAAATTTTGACACAGTAATTTTGTTTGATGAATCTTTTAAAAAACTGAGGAGGTATTTTGCATATCTTTTTTTTCATTTTCGTAATTTGTATTGCATTCTATAAAAATATTAGTTCATAACAGATCAGAAATTTAAAATAACTGGCCTTTTTCCTCAGGTAGTTTGAAAAACACACTCTAGAGATGCACTGTCCAATCCGGTAGCCACTAGCCACATGTGGCTAAATTAAAATTAAATAAAATGAGAAATGTAGTTTCTCAGTTGCACTAGCCACGTTTCAAGTTCTCAATGGCTACGTGTGACTAGTGCTTACCATACTGGACAGCACAGACACAGAATATTTTCATCACCACAGAAAGTTCTATCTGTTCTATTATAGAGACTTTTATCTATGCCCTATCTGGATTCTACTTATTTATAATTTAAGGTAAACATCTGAAAGCACATTTCAGCCTATTTGCTTAGTGAAACATTAAGCTGTAGACTGTAAACTCCTCGTGAGTAGGAACCCTGTCTCAGTGCATTTTGTTTTCCTGCTTCCTACCTCAAGATCTTGGCAATGGTACACTACAAATGTGCTGAGTTAGAATTACTCTGAAGTTATGAAACATATAATGAAAACAATTTTTTCTAGAGCTTATATTTTTATTTGAATGAAATAAAATGTTTAAATATTTAAAAATAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Gonadal</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Thyroid</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>LHCGR</Gene_Name>
    <Gene_Alias>LCGR; LGR2; LHRHR</Gene_Alias>
    <Gene_ID>3973</Gene_ID>
    <Genbank_ACCN>NM_000233</Genbank_ACCN>
    <Protein_ACCN>NP_000224</Protein_ACCN>
    <HGNC_ID>6585</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/3973</Gene_URL>
    <UCSC_ID>uc002rwu.4</UCSC_ID>
    <EMBL_ID>ENSG00000138039</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Hyperandrogenism</Disease_Name>
      <Disease_Detail>Hyperandrogenism</Disease_Detail>
      <Disease_DB>HYP043</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperandrogenism?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Luteinizing Hormone Resistance, Female</Disease_Name>
      <Disease_Detail>Luteinizing Hormone Resistance, Female</Disease_Detail>
      <Disease_DB>LTN005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/luteinizing_hormone_resistance_female?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Epithelial Cancer</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR094</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_epithelial_cancer?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leydig Cell Hypoplasia with Hypergonadotropic Hypogonadism</Disease_Name>
      <Disease_Detail>Leydig Cell Tumor</Disease_Detail>
      <Disease_DB>LYD006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leydig_cell_hypoplasia_with_hypergonadotropic_hypogonadism?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pseudohermaphroditism</Disease_Name>
      <Disease_Detail>Pseudohermaphroditism</Disease_Detail>
      <Disease_DB>PSD009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pseudohermaphroditism?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Precocious Puberty, Male</Disease_Name>
      <Disease_Detail>Precocious Puberty</Disease_Detail>
      <Disease_DB>PRC030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/precocious_puberty_male?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Male-Limited Precocious Puberty</Disease_Name>
      <Disease_Detail>Familial Male-Limited Precocious Puberty</Disease_Detail>
      <Disease_DB>FML157</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_male_limited_precocious_puberty?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leydig Cells Hypoplasia</Disease_Name>
      <Disease_Detail>Leydig Cells Hypoplasia</Disease_Detail>
      <Disease_DB>LYD003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leydig_cells_hypoplasia?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Amenorrhea</Disease_Name>
      <Disease_Detail>Amenorrhea</Disease_Detail>
      <Disease_DB>AMN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/amenorrhea?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leydig Cell Hypoplasia with Pseudohermaphroditism</Disease_Name>
      <Disease_Detail>Leydig Cell Tumor</Disease_Detail>
      <Disease_DB>LYD005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leydig_cell_hypoplasia_with_pseudohermaphroditism?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenoma</Disease_Name>
      <Disease_Detail>Adenoma</Disease_Detail>
      <Disease_DB>ADN018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenoma?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Cancer</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_cancer?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypogonadism</Disease_Name>
      <Disease_Detail>Hypogonadism</Disease_Detail>
      <Disease_DB>HYP080</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypogonadism?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leydig Cell Adenoma, Somatic, with Precocious Puberty</Disease_Name>
      <Disease_Detail>Leydig Cell Tumor</Disease_Detail>
      <Disease_DB>LYD007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leydig_cell_adenoma_somatic_with_precocious_puberty?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cushing's Syndrome</Disease_Name>
      <Disease_Detail>Cushing's Syndrome</Disease_Detail>
      <Disease_DB>CSH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cushings_syndrome?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Precocious Puberty</Disease_Name>
      <Disease_Detail>Precocious Puberty</Disease_Detail>
      <Disease_DB>PRC019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/precocious_puberty?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Testotoxicosis</Disease_Name>
      <Disease_Detail>Testotoxicosis</Disease_Detail>
      <Disease_DB>TST023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/testotoxicosis?search=LHCGR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leydig Cell Hypoplasia/agenesis</Disease_Name>
      <Disease_Detail>Leydig Cell Tumor</Disease_Detail>
      <Disease_DB>LYD004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leydig_cell_hypoplasia_agenesis?search=LHCGR#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>THEORETICAL MODEL OF THE LIGAND-BINDING REGION OF LUTROPIN RECEPTOR COMPLEXED WITH HUMAN CHORIONIC GONADOTROPIN</PDB_Title>
      <PDB_ID>1XUL</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/cgi/explore.cgi?pdbId=1XUL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Author>Jiang X</Author>
    </PDB>
    <PDB>
      <PDB_Title>THEORETICAL MODEL OF GLYCOPROTEIN HORMONE RECEPTOR</PDB_Title>
      <PDB_ID>1LUT</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/cgi/explore.cgi?pdbId=1LUT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Author>Jiang X</Author>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04917</Pathway_ID>
      <Pathway_Title>Prolactin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04917</Pathway_ID>
      <Pathway_Title>Prolactin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04080</Pathway_ID>
      <Pathway_Title>Neuroactive ligand-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04913</Pathway_ID>
      <Pathway_Title>Ovarian steroidogenesis</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD01800001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800020</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800021</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800022</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800023</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800024</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01800025</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01804005</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01804006</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>